Publication | Closed Access
Preclinical Pharmacokinetics and Safety of Sym004: A Synergistic Antibody Mixture Directed against Epidermal Growth Factor Receptor
40
Citations
14
References
2011
Year
Sym004 was well tolerated and did not induce any unexpected toxicities. The preclinical safety data enabled initiation of the ongoing clinical development.
| Year | Citations | |
|---|---|---|
Page 1
Page 1